** Shares of Fractyl Health GUTS.O fall 62.85% to 62 cents premarket

** Co says a small study showed that patients treated with its Revita procedure regained less weight after stopping popular weight-loss drugs than those given a sham treatment

** Revita is an experimental endoscopic procedure that modifies a part of the small intestine in patients who had stopped tirzepatide, the active ingredient in Eli Lilly's LLY.N blockbuster weight-loss drug

** Co says Revita patients regained 4.5% of their body weight over six months, compared with 7.5% in the sham group

** Says top-line six-month data from its larger study and possible U.S. marketing application could come in the second half of this year

** GUTS stock rose 6.8% in 2025

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))